HighTower Advisors
VYNE icon

HighTower Advisors’s VYNE Therapeutics VYNE Stock Holding History

HighTower Advisors’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-750
Closed -$50K – 3453
2021
Q2 		$50K Sell
750
-596
-44% -$47.2K ﹤0.01% 2893
2021
Q1 		$165K Buy
+1,346
New +$195K ﹤0.01% 2663
2020
Q4 		– Sell
-1,448
Closed -$175K – 2902
2020
Q3 		$175K Buy
1,448
+212
+17% +$24.7K ﹤0.01% 2133
2020
Q2 		$152K Buy
+1,236
New +$167K ﹤0.01% 2051

Other funds holding VYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HighTower Advisors's VYNE Position: Q3 2021 in Review

HighTower Advisors sold out of VYNE Therapeutics (VYNE) in Q3 2021, closing a stake of 750 shares — an estimated $50K sold.

HighTower Advisors first reported a position in VYNE in Q2 2020 and held it in 4 quarters. The position peaked at $175K in Q3 2020. 64 funds tracked by Wall St. Rank hold VYNE as of Q3 2021.

  • HighTower Advisors reported no remaining VYNE Therapeutics position as of Q3 2021 after selling out during the quarter.
  • HighTower Advisors sold 750 VYNE Therapeutics shares in Q3 2021, an estimated $50K.
  • HighTower Advisors first reported a position in VYNE Therapeutics in Q2 2020 and held it in 4 quarters.
  • HighTower Advisors's VYNE Therapeutics position peaked at $175K in Q3 2020.
  • 64 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q3 2021.

Based on HighTower Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.